RA Capital Management, L.P. 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:37 pm Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,181,818 4.700% | 86,682 (+2.80%) | Filing |
| 2024-02-14 9:08 pm Sale | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,095,136 6.100% | -313,570 (-9.20%) | Filing |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,408,706 9.990% | 1,801,847 (+112.13%) | Filing |
| 2021-08-13 4:31 pm Purchase | 2021-08-03 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 1,606,859 5.600% | 1,606,859 (New Position) | Filing |